Discordance in eGFR Equations Among Sarcopenic Older Adults and Implications for Antineoplastic Dosing
In a retrospective multicentre study of older adults receiving renally cleared antineoplastic agents, sarcopenia and the resulting discordance in creatinine-based eGFR equations were found to independently and significantly increase the risk of early severe toxicity, highlighting the need for improved renal function assessment to prevent functional overdose in this vulnerable population.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
In the complex world of cancer treatment, doctors rely on a simple blood test to decide how much medicine a patient should receive. This test measures a waste product called creatinine, which is naturally produced by the body's muscles. Because the kidneys filter this waste out of the blood, doctors use the level of creatinine to estimate how well the kidneys are working. If the kidneys are working well, they can handle a standard dose of powerful cancer drugs. If the kidneys are struggling, the dose must be lowered to prevent the medicine from building up to dangerous levels. This system works beautifully for most people, but it has a hidden flaw in older adults who have lost a significant amount of muscle mass. When muscle shrinks, the body produces less creatinine, even if the kidneys are failing. This tricks the blood test into showing a healthy number, leading doctors to believe the kidneys are strong when they are actually weak. The result is that patients may receive a dose of medicine that is too high for their body to handle, leading to severe side effects.
A new study involving nearly 1,500 older cancer patients across seven medical centers in Russia investigated exactly how often this dangerous misunderstanding happens and what it means for patient safety. The researchers focused on a condition called sarcopenia, which is the medical term for the age-related loss of muscle strength and mass. They looked at patients who were starting treatment with cancer drugs that are cleared from the body by the kidneys. Using routine CT scans taken just before treatment began, the team measured the amount of muscle in the lower back, a reliable indicator of total body muscle. They then compared the standard kidney function estimates, which rely on creatinine, against other methods that do not depend on muscle mass, such as a different blood marker called cystatin C or specialized formulas designed for older people.
The findings revealed a widespread and concerning disconnect. More than half of the patients studied had significant muscle loss. Among these patients, the standard kidney tests frequently gave a falsely optimistic reading. In nearly three out of four cases, the standard test suggested the kidneys were working well enough for a full dose, while the muscle-independent methods showed the kidneys were actually weaker and would require a lower dose. The researchers defined this situation as a "functional overdose," where the patient is effectively receiving too much medicine for their actual kidney capacity, even though the doctor followed the standard guidelines. This discrepancy was not just a minor statistical error; it had real-world consequences. Patients who had both muscle loss and this functional overdose faced a much higher risk of severe toxicity during the first two cycles of treatment. Specifically, nearly 60 percent of these vulnerable patients experienced severe side effects, compared to only about 21 percent of patients who had neither muscle loss nor the dosing mismatch.
The study also examined whether the type of cancer drug mattered, looking at eight different medications ranging from chemotherapy to targeted therapies. The problem appeared across the board, affecting patients regardless of which specific drug they received. While the researchers initially wondered if muscle loss would make the kidney test errors even larger, the data showed a more nuanced picture. The errors were significant in both patients with and without muscle loss, but the presence of muscle loss was the strongest predictor of who would suffer severe side effects. This suggests that muscle loss is a marker for a body that is less able to tolerate the stress of treatment, and when combined with an incorrect dose, the risk skyrockets. The study confirmed that relying on a single number from a standard blood test is insufficient for older patients, especially those who are frail or have lost muscle.
The researchers concluded that the current approach to dosing cancer drugs in older adults needs a safety check. They propose that when a standard kidney test and a muscle-independent method disagree significantly, doctors should treat this as a warning signal. Before starting treatment, clinicians should verify kidney function using methods that account for muscle loss, particularly for patients who appear frail or have low muscle mass on their scans. This does not mean giving everyone a lower dose blindly, but rather ensuring the dose is truly right for the individual's body. By catching these discrepancies early, doctors can avoid the severe toxicity that currently affects a large portion of older cancer patients, ensuring that life-saving treatments do not become life-threatening due to a simple miscalculation of kidney strength.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.